MLM Medical Labs
MLM Medical Labs is recorded as a service provider in 52 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 52 trials · Latest update first
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)
Sponsor Citryll B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
Sponsor Microbial Resource Management Health
- Start (EU)
- Latest update
- Estimated end
Microdystrophin (GNT0004) Gene Therapy Clinical Trial in Duchenne Muscular Dystrophy: A phase I/II/III study with a dose determination part followed by an efficacy and safety evaluation, quadruple blind placebo-controlled part and then by a long term safety follow up part, in ambulant boys
Sponsor Genethon
- Start (EU)
- Latest update
- Estimated end
A Phase 3b/4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex (EpiCom)
Sponsor Jazz Pharmaceuticals Research UK Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Enrollment was concentrated in the United States (53 of 79 participants), with 12 enrolled in Poland, 9 in Canada, and 5 in the United Kingdom.
- Optional adult self-report assessments had limited analyzed samples: 3 participants each for the ASR and PSQI, and 2 participants for PROMIS 1-4 positive affect.
- The protocol phase was revised from Phase 4 to Phase 3b/4 because EPIDIOLEX was not approved in Canada and some European countries.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
- Not reported
PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)
Sponsor Therakos Europe Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
(19429) A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)
Sponsor Freya Biosciences ApS
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
Sponsor Zealand Pharma A/S
- Start (EU)
- Latest update
- Estimated end
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Sponsor Iovance Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1-2 multicenter study to evaluate the safety and tolerability of intravenous ATA-100, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle muscular dystrophy (LGMD R9, formerly LGMD2I)
Sponsor Atamyo Therapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
Sponsor Ribocure Pharmaceuticals AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1
Sponsor Vanqua Bio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD
Sponsor Ribocure Pharmaceuticals AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Twenty participants from one Japanese site were excluded from all analyses because of Good Clinical Practice violations.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for MLM Medical Labs?
The 2026-10-09 snapshot links MLM Medical Labs to 52 distinct CTIS trials. Recorded services include Laboratory services, Biomarker analysis - PD analysis, BIOMARKER ANALYSIS (Germany ONLY), Blood store (determination of myostatin levels), among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for MLM Medical Labs?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Genetic and Congenital Disorders, Neurology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to MLM Medical Labs conducted?
The linked trials record locations in 23 countries, including Germany, Spain, France, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where MLM Medical Labs delivered services.
What can this page tell me about MLM Medical Labs's trial experience?
Browse 52 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under MLM Medical Labs. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mlm Medical Labs GmbH
- Mlm Medical Labs LLC